- Conditions
- Hepatobiliary Cancers
- Interventions
- Durvalumab-based combination therapies in observational study setting
- Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 4,490 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2025 · Synced May 21, 2026, 10:12 PM EDT